Shares of Merit Medical Systems, Inc. (NASDAQ:MMSI – Get Free Report) have been given a consensus rating of “Moderate Buy” by the twelve brokerages that are presently covering the company, Marketbeat reports. Three investment analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating on the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $100.00.
MMSI has been the topic of several analyst reports. Raymond James Financial reiterated an “outperform” rating and set a $100.00 price target on shares of Merit Medical Systems in a research note on Friday, July 31st. Zacks Research upgraded Merit Medical Systems from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, August 25th. BTIG Research reaffirmed a “buy” rating and issued a $105.00 target price on shares of Merit Medical Systems in a report on Tuesday, August 11th. Robert W. Baird set a $98.00 target price on Merit Medical Systems in a research report on Friday, July 31st. Finally, Wells Fargo & Company boosted their price target on Merit Medical Systems from $74.00 to $83.00 and gave the company an “equal weight” rating in a report on Friday, July 31st.
Get Our Latest Stock Report on MMSI
Institutional Investors Weigh In On Merit Medical Systems
Merit Medical Systems Trading Up 1.2%
Merit Medical Systems stock opened at $89.60 on Wednesday. Merit Medical Systems has a 52-week low of $59.74 and a 52-week high of $94.75. The company has a market cap of $5.35 billion, a P/E ratio of 37.02, a P/E/G ratio of 2.21 and a beta of 0.49. The company has a quick ratio of 2.79, a current ratio of 4.20 and a debt-to-equity ratio of 0.44. The business has a 50-day simple moving average of $81.85 and a two-hundred day simple moving average of $73.22.
Merit Medical Systems (NASDAQ:MMSI – Get Free Report) last posted its quarterly earnings data on Thursday, July 30th. The medical instruments supplier reported $1.19 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.96 by $0.23. The company had revenue of $418.84 million for the quarter, compared to the consensus estimate of $405.25 million. Merit Medical Systems had a net margin of 9.22% and a return on equity of 13.75%. The firm’s revenue was up 9.5% compared to the same quarter last year. During the same quarter last year, the firm posted $1.01 earnings per share. Merit Medical Systems has set its FY 2026 guidance at 4.250-4.350 EPS. Analysts predict that Merit Medical Systems will post 3.84 EPS for the current year.
About Merit Medical Systems
Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company’s product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.
Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.
See Also
- Five stocks we like better than Merit Medical Systems
- Revolution Medicines Got Its Breakthrough—What Moves It Next?
- Retail Earnings Just Exposed a Bigger Divide in the U.S. Consumer Economy
- FB Financial’s Southern Expansion and Buybacks Drive Analyst Optimism
- AST SpaceMobile Stock Soared 12%—This Was the Catalyst
Receive News & Ratings for Merit Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merit Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.
